Loading...
XNAS
KTTAW
Market cap6mUSD
Jun 12, Last price  
0.02USD
1D
32.67%
1Q
-0.50%
IPO
-97.72%
Name

Pasithea Therapeutics Corp

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
0k
015,062486,55900
Net income
-13.90b
L+87,012.40%
-40,984-2,174,029-13,056,481-15,961,658-13,904,584,000
CFO
-13.92b
-38,689-3,174,058-14,561,9210-13,923,438,000

Profile

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.
IPO date
Aug 13, 2021
Employees
15
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑12
Income
Revenues
487
3,130.37%
Cost of revenue
7,198,494
15,979
15,303
Unusual Expense (Income)
NOPBT
(7,198,494)
(15,979)
(14,816)
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
(7,198,494)
(15,979)
(14,816)
Net income
(13,904,584)
87,012.40%
(15,962)
22.25%
(13,056)
500.57%
Dividends
(359,656)
Dividend yield
10,416.79%
Proceeds from repurchase of equity
(3,726)
(3,206)
BB yield
41.05%
19.79%
Debt
Debt current
82
263
Long-term debt
82
1,590
Deferred revenue
Other long-term liabilities
162,172
84
141
Net debt
(6,922,729)
(16,168)
(31,293)
Cash flow
Cash from operating activities
(13,923,438)
(14,562)
CAPEX
(34)
(2,139)
Cash from investing activities
399
(2,062)
Cash from financing activities
4,517,634
(3,726)
(3,206)
FCF
(7,198,396)
(14,947)
(16,049)
Balance
Cash
6,922,729
16,331
33,147
Long term investments
Excess cash
6,922,729
16,331
33,123
Stockholders' equity
(49,589,949)
(35,323)
(19,340)
Invested Capital
64,534,797
58,888
62,905
ROIC
ROCE
EV
Common stock shares outstanding
1,096
1,227
1,262
Price
3.15
-57.43%
7.40
-42.34%
12.83
-63.75%
Market cap
3,453
-61.96%
9,077
-43.97%
16,201
-60.22%
EV
(6,919,276)
(7,091)
(15,092)
EBITDA
(7,179,629)
(15,331)
(14,784)
EV/EBITDA
0.96
0.46
1.02
Interest
102
Interest/NOPBT